Rebecca Burdine, PhD

Princeton, New Jersey, United States
Rebecca Burdine joined the faculty at Princeton in 2003. Her lab focuses on understanding the mechanisms that control left-right patterning and asymmetric organ morphogenesis, and develops zebrafish models for rare diseases. She was named the 44th Mallinckrodt Scholar for the Edward Mallinckrodt Jr. Foundation, received a Scientist Development Career Award from the American Heart Association in 2003, and was elected as Fellow to the American Association for the Advancement of Science (AAAS) in 2018. She is on the Editorial boards for Cell Reports and Zebrafish, and regularly serves on grant review panels for the NIH and NSF.

Dr. Burdine graduated summa cum laude from Western Kentucky University, majoring in Recombinant Gene Technology with a minor in Chemistry. She received her Ph.D. from Yale University and conducted her postdoctoral research at the Skirball Institute of Biomolecular Medicine at New York University.

Dr. Burdine is also parent to a child with Angelman Syndrome. Dr. Burdine currently serves on the Board and Scientific Advisory Committee for the Angelman Syndrome Foundation, and as a clinical trial steering committee member for Ovid Therapeutics. She previously served as Chief Scientific Officer for the Pitt-Hopkins Research Foundation, and was a founding member and former Chief Scientific Officer for the Foundation for Angelman Syndrome Therapeutics.
Speaking In
2:40 PM - 3:15 PM (EDT)
Thursday, October 29
Join us for a fireside chat moderated by Jeremy Levin, Chairman & CEO, Ovid Therapeutics, with…